ESCMID eAcademy

ePosters are only viewable by those with a valid ECCMID 2021 registration.
If you already have a registration, please login to the online platform here.
If you are not yet registered, you can do so here.
Abstract
Discussion Forum (0)
Abstract number: 444

Session Type: 1,5-hour Oral Session

Session Title: 1,5-hour Oral Session

Authors(s): K. Hagman (1), M. Hedenstierna (2), J. Rudling (2), P. Gille-Johnson (2), B. Hammas (3), M. Grabbe (3), J. Jakobsson (4), J. Dillner (5), J. Ursing (2)

Authors Affiliations(s): (1) Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Sweden, (2) Department of Infectious Diseases, Danderyd Hospital, Sweden, (3) Department of Microbiology, Karolinska University Hospital, Sweden, (4) Department of Anesthesia and Intensive Care, Danderyd Hospital, Sweden, (5) Karolinska University Laboratory, Sweden

Background:

SARS-CoV-2 viremia at hospital admission is associated with high risk for ICU-care and mortality. Data on duration of viremia are limited. 

Methods:

Time to serum viral clearance was studied in a cohort of viremic adults hospitalized for COVID-19. Serum viral clearance was defined as the day after the last positive serum sample.

Results:

A total of 121 patients were included. Median age was 62 (IQR 52-71) years and 68% were males. Kaplan-Meier estimate of median time from symptom onset to serum viral clearance was 15 (IQR 14-16) days. Median time to serum viral clearance was delayed in non-survivors (20 [IQR 15-25] days, n = 40), compared to survivors (14 [IQR 13-15] days, n = 81). The median time to serum viral clearance was shorter for corticosteroid treated (12 [IQR 11-17] days, n =22) compared to untreated patients (15 [IQR 14-17] days, n = 99). In-hospital mortality (subdistribution hazard ratio [SHR] 0.21 [95% CI 0.11-0.41]) and immunosuppression (SHR 0.34 [95% CI 0.18-0.62]) were associated with a reduced incidence of serum viral clearance in a multivariate competing risk regression analysis. Receiving corticosteroids was associated with an increased (SHR 1.79 [95% CI 1.08-2.97]) incidence of serum viral clearance. CT values increased over time until SARS-CoV-2 RNA was no longer detected which coincided with defervescence and decreasing C-reactive protein. 

Conclusions:

Time from symptom onset to serum viral clearance was longer in non-survivors compared to survivors. Time to serum viral clearance was shorter in patients treated with corticosteroids, however numbers are limited.

Keyword(s): viremia, RNAemia, SARS-CoV-2

Abstract number: 444

Session Type: 1,5-hour Oral Session

Session Title: 1,5-hour Oral Session

Authors(s): K. Hagman (1), M. Hedenstierna (2), J. Rudling (2), P. Gille-Johnson (2), B. Hammas (3), M. Grabbe (3), J. Jakobsson (4), J. Dillner (5), J. Ursing (2)

Authors Affiliations(s): (1) Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Sweden, (2) Department of Infectious Diseases, Danderyd Hospital, Sweden, (3) Department of Microbiology, Karolinska University Hospital, Sweden, (4) Department of Anesthesia and Intensive Care, Danderyd Hospital, Sweden, (5) Karolinska University Laboratory, Sweden

Background:

SARS-CoV-2 viremia at hospital admission is associated with high risk for ICU-care and mortality. Data on duration of viremia are limited. 

Methods:

Time to serum viral clearance was studied in a cohort of viremic adults hospitalized for COVID-19. Serum viral clearance was defined as the day after the last positive serum sample.

Results:

A total of 121 patients were included. Median age was 62 (IQR 52-71) years and 68% were males. Kaplan-Meier estimate of median time from symptom onset to serum viral clearance was 15 (IQR 14-16) days. Median time to serum viral clearance was delayed in non-survivors (20 [IQR 15-25] days, n = 40), compared to survivors (14 [IQR 13-15] days, n = 81). The median time to serum viral clearance was shorter for corticosteroid treated (12 [IQR 11-17] days, n =22) compared to untreated patients (15 [IQR 14-17] days, n = 99). In-hospital mortality (subdistribution hazard ratio [SHR] 0.21 [95% CI 0.11-0.41]) and immunosuppression (SHR 0.34 [95% CI 0.18-0.62]) were associated with a reduced incidence of serum viral clearance in a multivariate competing risk regression analysis. Receiving corticosteroids was associated with an increased (SHR 1.79 [95% CI 1.08-2.97]) incidence of serum viral clearance. CT values increased over time until SARS-CoV-2 RNA was no longer detected which coincided with defervescence and decreasing C-reactive protein. 

Conclusions:

Time from symptom onset to serum viral clearance was longer in non-survivors compared to survivors. Time to serum viral clearance was shorter in patients treated with corticosteroids, however numbers are limited.

Keyword(s): viremia, RNAemia, SARS-CoV-2

Duration of SARS-CoV-2 viremia and its correlation to inflammatory parameters in patients hospitalised for COVID-19
Dr. Karl Hagman
Dr. Karl Hagman
Affiliations:
Karolinska Institutet, Stockholm, Sweden
ESCMID eAcademy. Hagman K. 07/09/2021; 333006; 444;
user
Dr. Karl Hagman
Affiliations:
Karolinska Institutet, Stockholm, Sweden
Abstract
Discussion Forum (0)
Abstract number: 444

Session Type: 1,5-hour Oral Session

Session Title: 1,5-hour Oral Session

Authors(s): K. Hagman (1), M. Hedenstierna (2), J. Rudling (2), P. Gille-Johnson (2), B. Hammas (3), M. Grabbe (3), J. Jakobsson (4), J. Dillner (5), J. Ursing (2)

Authors Affiliations(s): (1) Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Sweden, (2) Department of Infectious Diseases, Danderyd Hospital, Sweden, (3) Department of Microbiology, Karolinska University Hospital, Sweden, (4) Department of Anesthesia and Intensive Care, Danderyd Hospital, Sweden, (5) Karolinska University Laboratory, Sweden

Background:

SARS-CoV-2 viremia at hospital admission is associated with high risk for ICU-care and mortality. Data on duration of viremia are limited. 

Methods:

Time to serum viral clearance was studied in a cohort of viremic adults hospitalized for COVID-19. Serum viral clearance was defined as the day after the last positive serum sample.

Results:

A total of 121 patients were included. Median age was 62 (IQR 52-71) years and 68% were males. Kaplan-Meier estimate of median time from symptom onset to serum viral clearance was 15 (IQR 14-16) days. Median time to serum viral clearance was delayed in non-survivors (20 [IQR 15-25] days, n = 40), compared to survivors (14 [IQR 13-15] days, n = 81). The median time to serum viral clearance was shorter for corticosteroid treated (12 [IQR 11-17] days, n =22) compared to untreated patients (15 [IQR 14-17] days, n = 99). In-hospital mortality (subdistribution hazard ratio [SHR] 0.21 [95% CI 0.11-0.41]) and immunosuppression (SHR 0.34 [95% CI 0.18-0.62]) were associated with a reduced incidence of serum viral clearance in a multivariate competing risk regression analysis. Receiving corticosteroids was associated with an increased (SHR 1.79 [95% CI 1.08-2.97]) incidence of serum viral clearance. CT values increased over time until SARS-CoV-2 RNA was no longer detected which coincided with defervescence and decreasing C-reactive protein. 

Conclusions:

Time from symptom onset to serum viral clearance was longer in non-survivors compared to survivors. Time to serum viral clearance was shorter in patients treated with corticosteroids, however numbers are limited.

Keyword(s): viremia, RNAemia, SARS-CoV-2

Abstract number: 444

Session Type: 1,5-hour Oral Session

Session Title: 1,5-hour Oral Session

Authors(s): K. Hagman (1), M. Hedenstierna (2), J. Rudling (2), P. Gille-Johnson (2), B. Hammas (3), M. Grabbe (3), J. Jakobsson (4), J. Dillner (5), J. Ursing (2)

Authors Affiliations(s): (1) Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Sweden, (2) Department of Infectious Diseases, Danderyd Hospital, Sweden, (3) Department of Microbiology, Karolinska University Hospital, Sweden, (4) Department of Anesthesia and Intensive Care, Danderyd Hospital, Sweden, (5) Karolinska University Laboratory, Sweden

Background:

SARS-CoV-2 viremia at hospital admission is associated with high risk for ICU-care and mortality. Data on duration of viremia are limited. 

Methods:

Time to serum viral clearance was studied in a cohort of viremic adults hospitalized for COVID-19. Serum viral clearance was defined as the day after the last positive serum sample.

Results:

A total of 121 patients were included. Median age was 62 (IQR 52-71) years and 68% were males. Kaplan-Meier estimate of median time from symptom onset to serum viral clearance was 15 (IQR 14-16) days. Median time to serum viral clearance was delayed in non-survivors (20 [IQR 15-25] days, n = 40), compared to survivors (14 [IQR 13-15] days, n = 81). The median time to serum viral clearance was shorter for corticosteroid treated (12 [IQR 11-17] days, n =22) compared to untreated patients (15 [IQR 14-17] days, n = 99). In-hospital mortality (subdistribution hazard ratio [SHR] 0.21 [95% CI 0.11-0.41]) and immunosuppression (SHR 0.34 [95% CI 0.18-0.62]) were associated with a reduced incidence of serum viral clearance in a multivariate competing risk regression analysis. Receiving corticosteroids was associated with an increased (SHR 1.79 [95% CI 1.08-2.97]) incidence of serum viral clearance. CT values increased over time until SARS-CoV-2 RNA was no longer detected which coincided with defervescence and decreasing C-reactive protein. 

Conclusions:

Time from symptom onset to serum viral clearance was longer in non-survivors compared to survivors. Time to serum viral clearance was shorter in patients treated with corticosteroids, however numbers are limited.

Keyword(s): viremia, RNAemia, SARS-CoV-2

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies